Victoria Werth, MD

Victoria Werth, MD, professor of dermatology and rheumatology at the University of Pennsylvania, recently discussed brepocitinib's FDA approval for dermatomyositis and what the VALOR trial data mean for patients and clinicians.

Victoria Werth, MD, reviews brepocitinib's boxed warning and expanded treatment options for dermatomyositis.

Victoria Werth, MD, discusses the FDA approval of brepocitinib for dermatomyositis and its supporting VALOR trial data.

LILAC data shows litifilimab rapidly improves CLE skin scores, fueling AMETHYST phase 3 and supporting FDA breakthrough for cutaneous lupus patients.

Victoria Werth, MD, highlights CLE treatment gaps and how BDCA2-targeting litifilimab may quickly curb interferon-driven skin disease with less toxicity.